A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

被引:44
作者
Reff, ME [1 ]
Heard, C [1 ]
机构
[1] Idec Pharmaceut Corp, San Diego, CA 92191 USA
关键词
antibody-drug conjugates; bispecific antibodies; monoclonal antibodies; monoclonal antibody effector function; monoclonal antibody pharmacokinetics; single chain Fv;
D O I
10.1016/S1040-8428(01)00132-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although monoclonal antibodies have high specificity, their usefulness in the clinic, especially against solid tumors, has been limited. This arises in part from the inability of antibody molecules to penetrate into the tumor and kill the tumor cells. In addition, natural cytotoxic effects of antibodies, mediated through complement or Fc receptors, may not be sufficient to kill malignant cells. This review will present some of the antibody modifications used to increase efficacy. Modified recombinant antibodies have been designed to be more cytotoxic (immunotoxins), to increase natural effector functions (bivalent antibodies, antibody-fusion molecules, multimeric antibodies, directed mutations in Fc region), or to pretarget cells for concentration of cytotoxic drugs. This review will also focus on engineering of smaller versions of antibodies that retain specificity (single chain Fvs, Fabs, Fab(2)s. minibodies. domain deleted antibodies) and have increased penetrability of solid tumors. Many of these antibody modifications may result in antigenic compounds which can limit repeat administration, Clinical experiences will be highlighted if information is available. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:25 / 35
页数:11
相关论文
共 86 条
[1]   PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL-ANTIBODY USED IN CADAVERIC RENAL-TRANSPLANTATION [J].
AMLOT, PL ;
RAWLINGS, E ;
FERNANDO, ON ;
GRIFFIN, PJ ;
HEINRICH, G ;
SCHREIER, MH ;
CASTAIGNE, JP ;
MOORE, R ;
SWENY, P .
TRANSPLANTATION, 1995, 60 (07) :748-756
[2]  
ARIZONO H, 1994, ARZNEIMITTEL-FORSCH, V44-2, P890
[3]   Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome [J].
Baluna, R ;
Rizo, J ;
Gordon, BE ;
Ghetie, V ;
Vitetta, ES .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3957-3962
[4]   SINGLE-CHAIN IMMUNOTOXINS DIRECTED AT THE HUMAN TRANSFERRIN RECEPTOR CONTAINING PSEUDOMONAS EXOTOXIN-A OR DIPHTHERIA-TOXIN - ANTI-TFR(FV)-PE40 AND DT388-ANTI-TFR(FV) [J].
BATRA, JK ;
FITZGERALD, DJ ;
CHAUDHARY, VK ;
PASTAN, I .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (04) :2200-2205
[5]  
BEHR T, 1995, CANCER RES, V55, pS5777
[6]  
BIELA BH, 1999, P AM ASS CANC RES, V40
[7]   ANTI-TAC-H, A HUMANIZED ANTIBODY TO THE INTERLEUKIN-2 RECEPTOR, PROLONGS PRIMATE CARDIAC ALLOGRAFT SURVIVAL [J].
BROWN, PS ;
PARENTEAU, GL ;
DIRBAS, FM ;
GARSIA, RJ ;
GOLDMAN, CK ;
BUKOWSKI, MA ;
JUNGHANS, RP ;
QUEEN, C ;
HAKIMI, J ;
BENJAMIN, WR ;
CLARK, RE ;
WALDMANN, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2663-2667
[8]  
BUCHSBAUM DJ, 1990, CANCER RES, V50, pS993
[9]  
BUCHSBAUM DJ, 1999, CLIN CANCER RES, P5
[10]   HUMAN-ANTIBODY EFFECTOR FUNCTION [J].
BURTON, DR ;
WOOF, JM .
ADVANCES IN IMMUNOLOGY, 1992, 51 :1-+